eosinophilic esophagitis market

Oct 07, 2024

After more than ten years without significant therapeutic advancements in chronic obstructive pulmonary disease (COPD), patients with this progressive condition now have two new treatment options, with more likely to follow. Regeneron and Sanofi recently announced that the FDA has broadened the use of the highly...

Feb 09, 2024

Sanofi and Regeneron are prioritizing pediatric care, particularly in their recent progress with the potent anti-inflammatory drug, Dupixent. On January 25, 2024, the FDA approved Dupixent, an IL-4 receptor alpha antagonist, for the treatment of eosinophilic esophagitis (EoE) in children aged 1 to 11, weighing at l...

Jan 09, 2023

Eosinophilic Esophagitis (EoE) is a chronic inflammatory ailment that is immune-mediated. It is characterized by an increased number of eosinophils infiltrating the esophagus, thus, impacting one’s fundamental eating ability. It affects both adults and children and is caused by allergens; food antigens are consider...